Stifel Financial Corp Lowers Position in IQVIA Holdings Inc. (NYSE:IQV)

Stifel Financial Corp reduced its stake in shares of IQVIA Holdings Inc. (NYSE:IQV - Free Report) by 4.0% during the third quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 362,993 shares of the medical research company's stock after selling 15,134 shares during the period. Stifel Financial Corp owned 0.20% of IQVIA worth $86,019,000 at the end of the most recent reporting period.

Other hedge funds also recently made changes to their positions in the company. FMR LLC raised its stake in IQVIA by 38.7% during the 3rd quarter. FMR LLC now owns 2,887,342 shares of the medical research company's stock valued at $684,213,000 after purchasing an additional 804,963 shares during the period. B. Metzler seel. Sohn & Co. Holding AG bought a new stake in IQVIA in the 3rd quarter valued at $147,683,000. 1832 Asset Management L.P. lifted its stake in IQVIA by 472.3% in the 2nd quarter. 1832 Asset Management L.P. now owns 456,335 shares of the medical research company's stock worth $96,487,000 after purchasing an additional 376,595 shares in the last quarter. Renaissance Technologies LLC bought a new position in shares of IQVIA during the 2nd quarter valued at about $70,610,000. Finally, Impax Asset Management Group plc grew its position in shares of IQVIA by 19.3% during the second quarter. Impax Asset Management Group plc now owns 1,635,201 shares of the medical research company's stock valued at $344,998,000 after purchasing an additional 264,555 shares in the last quarter. 89.62% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

A number of equities analysts recently commented on the company. Leerink Partners reissued an "outperform" rating and set a $248.00 price target (down from $260.00) on shares of IQVIA in a research note on Tuesday, November 19th. Morgan Stanley lowered their target price on IQVIA from $280.00 to $265.00 and set an "overweight" rating for the company in a research report on Monday, November 4th. Deutsche Bank Aktiengesellschaft decreased their price target on shares of IQVIA from $270.00 to $265.00 and set a "buy" rating on the stock in a research note on Friday, November 1st. Robert W. Baird dropped their price objective on shares of IQVIA from $256.00 to $223.00 and set a "neutral" rating for the company in a research note on Friday, November 1st. Finally, Truist Financial decreased their target price on shares of IQVIA from $286.00 to $265.00 and set a "buy" rating on the stock in a research report on Monday, November 4th. Five investment analysts have rated the stock with a hold rating, fourteen have assigned a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat.com, the company has a consensus rating of "Moderate Buy" and a consensus price target of $256.50.

IQVIA Trading Up 1.4 %

Shares of NYSE IQV traded up $2.70 during mid-day trading on Friday, reaching $202.63. The company had a trading volume of 1,388,125 shares, compared to its average volume of 2,002,141. IQVIA Holdings Inc. has a 52 week low of $187.62 and a 52 week high of $261.73. The business's 50-day moving average is $215.18 and its 200-day moving average is $225.11. The stock has a market cap of $36.78 billion, a price-to-earnings ratio of 26.59, a price-to-earnings-growth ratio of 2.09 and a beta of 1.49. The company has a current ratio of 0.81, a quick ratio of 0.81 and a debt-to-equity ratio of 1.76.

IQVIA Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.